PRICE FROM £42.50 - £1,411.20


Hughes Healthcare Rapid Antigen Test

  • Approved for Home Use by Non-Healthcare Professionals
  • Contains Individually Sealed Tests
  • Delivered via Royal Mail Special Delivery 
  • Results in 15 minutes
  • Sensitivity 97.1%, Specificity 99.5%

Available in consignments of 5, 10 and 240 units. 

The Private Harley Street Clinic is pleased to offer the Hughes Healthcare Rapid Antigen Test.

Non-Invasive, Lower Nostril, LFD Rapid Antigen Test.

This test is registered with the MHRA and has a CE Mark for home use by non-healthcare professionals in the UK and EU.

This test is chosen by Governments and companies around the world as it provides results in 15 minutes via a quick and simple sample collection method designed to minimise patient discomfort (the swab is only inserted 1-2cm into the lower nostril).

Each Box Contains:

  • Individually sealed test cassettes
  • Individually sealed swab
  • Pre-filled buffer tube
  • Instructions

    Hughes Healthcare Flowflex Rapid Antigen Test is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2 present along the mucosa wall on the inside of the nostril.

    The test is taken to:

    • Diagnose infection
    • Test following infection to see if the virus has been cleared
    • Screen asymptomatic individuals to detect if they carry virus and are potentially infectious

    This is a 'Point of Care Test', meaning the results are provided to you on the day of the test. The test takes roughly 15 minutes to provide a result and you will be provided with a confirmation email and certificate of this result by the end of the day.

    These tests are CE Marked and MHRA Registered. 

    The test has a Sensitivity of 97.1% and a Specificity of 99.5%.

    Sensitivity concerns the false negative rate and is expressed as a percentage: out of 100 truly positive patients, how many are detected as positive by the test? The higher the sensitivity, the fewer the numbers of false negatives. In the USA, sensitivity is often called positive percent agreement (PPA).

    Specificity concerns the false positive rate and is expressed as a percentage: out of 100 truly negative patients, how many are detected as negative by the test? The higher the specificity, the fewer the numbers of false positives. In the USA, specificity is often called negative percent agreement (NPA).

    The extraction buffer includes components to dissociate viral proteins from their surfaces to be used as a target for the test. The method of the extraction buffer is used to prepare the test sample by dissolving the virus shell, which also deactivates the virus.

    The test kit includes an extraction buffer that is used to prepare the specimen for testing purposes. The extraction buffer IS NOT transport media and should not be used to preserve or transport specimens.

    The Rapid COVID-19 Antigen Test is for lower nostril rapid antigen specimen only. The test can only be used with the swab provided in the kit.

    The specimen should be tested immediately after collection. The specimen can be retained up to 1 hour following collection if immediate testing of specimens is not possible. Dispose of the specimen and recollect if retained for more than 1 hour.

    The device should never be frozen. If refrigerated, allow the test kit components to reach room temperature before use.

    Before taking the test, it is important to understand the following.

    1. You should not use one of these tests if you have previously tested positive from a PCR test in the previous 90 days, as this can return a false result.
    2. You should not use any nasal medication for 24 hours prior to testing as this can spoil the sample.
    3. Negative results do not rule out SARS-CoV-2 infection, particularly those who have been in contact with the virus. Follow up testing with a molecular diagnostic test should be considered to rule out infection in these individuals. Use of this test is limited to laboratories certified to perform high complexity testing, including testing at point-of-care when the site is covered by the laboratory's CLIA certificate of high-complexity testing.